The cancer treatment landscape is rapidly changing with new discoveries and expert guidance emerging. As research, testing and treatment strategies continue to evolve, clinicians must keep abreast of the latest data on molecular mechanisms, emerging therapies, current standards of care, expert guideline updates, and new strategies for treatment. Whether you are looking for education on the value and interpretation of real-world evidence for clinical decision making, translation of efficacy and safety of therapeutic agents to decisions for your patients, or resources to share with patients and families navigating their cancer journey, you’ll find educational activities and resources here to help improve your knowledge and help your patients better take part in their care.

Our activities offer many credit types, including CME, AAFP Prescribed Credit, CNE, CPE, ABIM MOC, and ABP MOC. Each activity has been designed to meet the requirements for CME for MIPS. See each activity’s information page for the exact credit type and amount of credit offered.

The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: Guidance for Today and the Path Forward


Participate Now!
The discovery of molecular alterations that drive tumor initiation and progression has revolutionized the treatment strategy for non-small cell lung cancer (NSCLC) by matching targeted therapies to a specific mutation, leading to significantly improved therapeutic efficacy. However, despite the initial effectiveness of targeted therapy for NSCLC, most patients ultimately develop acquired resistance with subsequent disease progression, making it imperative for clinicians to receive up-to-date education on evaluating new therapeutic options to improve outcomes and better tailor treatment strategies.

In this CME Outfitters OnDemand, integrations of animated 3-D models will provide visual representation of the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC to complement expert faculty insights and evidence supporting testing strategies to identify predictive biomarkers, emerging treatment options for advanced or metastatic NSCLC, and best practices for managing patients with lung cancer in the face of COVID-19 and beyond.

Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape


Participate Now!
This CME Outfitters Live and OnDemand webcast will provide up-to-date education on this rapidly evolving field, in order to better tailor treatment strategies, leading to improved patient outcomes. Additionally, faculty will discuss COVID-19 and its impact on patients with BC.

Maintenance Therapy in Metastatic Urothelial Carcinoma (mUC): Integrating Current Treatment Options into Practice


Participate Now!
The first episode of this CMEOCast podcast series on practice-changing treatment advances in mUC focuses on examining current 1L treatment options, including maintenance therapy to optimize patient outcomes in mUC.

Treatment and Sequencing Strategies: Providing the Best Care for Patients with Metastatic Urothelial Carcinoma (mUC)


Participate Now!
This CMEOCast podcast features expert faculty evaluating efficacy data for 1L and 2L sequencing strategies in patients with mUC highighting immune checkpoint inhibitors and other novel agents, as well as provide strategies for managing adverse events during treatment.

Informed Decisions: Sharing Safety and Efficacy Data with Patients with Metastatic Urothelial Carcinoma (mUC)


Participate Now!
The final episode of this CMEOCast podcast series on providing the best care for patients with mUC focuses on helping clinicians stay abreast of the evolving evidence for maintenance immunotherapy regimens, providing patients with education that will empower them to be stakeholders in their care, and considering patient perspectives and preferences as a part of shared decision-making, in order to choose the optimal evidence-based course of treatment.

The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: 3D Animation

View this animation to understand the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC

Whiteboard Animation: Real-World Evidence in Metastatic Breast Cancer

In oncology, real-world evidence, or RWE, refers to evidence derived from the use and analysis of real-world data, or RWD, which are data obtained outside the context of randomized controlled trials, or RCTs. View this animation to learn more about RWE in Metastatic Breast Cancer.

You may have a million questions about bladder cancer, but where do you to start? CME Outfitters talked with patients and caregivers to find out what information was useful for them and what questions they asked their physician and care team during visits. We compiled resources and questions to ask that we hope will be helpful as you and your family navigate this journey.

What You Need to Know to Share the Metastatic Urothelial Carcinoma (mUC) Decision-Making with Your Physician

What Questions Should I Be Asking About My Bladder Cancer?

You may have a million questions, but where do you to start? CME Outfitters talked with patients and caregivers to find out what questions they asked their physician and care team during visits. Here are some questions they found useful to ask!

Frequently Asked Questions When Going Through Treatment for Bladder Cancer

What Questions Should I Be Asking About Treatment?

What Questions Should I Be Asking? Understanding Bladder Cancer

What Questions Should I Be Asking? Communicating with the Care Team

Things to Share with My Care Team Today

Care Team Contact Info

Definitions to Prepare You for Discussions with Your Care Team

Breast Cancer

American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP): Guideline on estrogen and progesterone receptor testing in breast cancer

ASCO/CAP: Clinical practice guideline focused update on human epidermal growth factor receptor 2 testing in breast cancer, update

ASCO: Clinical practice guideline update on recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases

ASCO: Clinical practice guideline update on systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer

ASCO: Guideline on management of male breast cancer

ASCO: Endorsement of the Cancer Care Ontario guideline –Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer, update (2019)

Lung Cancer

ASCO and Ontario Health (Cancer Care Ontario [CCO]): Joint guideline update on therapy for stage IV non-small-cell lung cancer without driver alterations

National Cancer Institute (NCI): Non-small-cell lung cancer–Health professional version

ASCO: Clinical practice guideline on systemic therapy for stage IV non-small-cell lung cancer, update

American Thoracic Society (ATS): Official policy statement for evaluating molecular biomarkers for the early detection of lung cancer

European Society for Medical Oncology (ESMO): Metastatic non-small-cell lung cancer –Clinical practice guidelines for diagnosis, treatment, and follow-up